Project CBD

NOVEMBER 8, 2021

Psilocybin, the psychedelic mushroom extract, has been fast-tracked by the FDA to treat depression, but doctors still can’t use it in their practice.

DEA 150

DEA Patients Extraction 150

Cannabis Law Report

MARCH 10, 2021

Marijuana Moment reports A Seattle doctor hoping to expand access to psilocybin mushrooms for terminally ill cancer patients is taking… Read More. The post USA: Dr Suing DEA Over Right To Give Patients Psilocybin Treatment first appeared on Cannabis Law Report.

DEA 85

DEA Treatment Patients Access 85

WeedAdvisor

JULY 4, 2019

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety.

DEA 111

DEA Research and Development Clinical Trials Cultivation 111

MJ Business Attorneys

JUNE 29, 2018

Epidiolex is the first drug the FDA has approved that contains a substance derived from marijuana, and it is also the first drug approved by the FDA to be used to treat patients with Dravet syndrome. Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. In the recent case Hemp Industries Associations v.

DEA 113

DEA CBD Pharmaceutical Research and Development 113

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We BRC) told The Cannigma this week. Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Leafly

MAY 10, 2022

Many were arrested protesting the DEA's decision to not recognize the Right To Try law, allowing psilocybin use for terminally ill patients looking to ease end-of-life anxiety and distress. The post Protestors of psilocybin ban arrested at DEA headquarters appeared first on Leafly.

DEA 98

DEA Patients Law 98

NORML

JANUARY 17, 2019

As the result of a lawsuit, DEA Administrative Law Judge Mary Ellen Bittner in 2007 ruled that expanding the pool of federally licensed providers would be “in the public interest.” The agency ultimately rejected her decision. Click here to send a message to your federal lawmaker and urge them to support the measure. .

Clinical Trials 230

Clinical Trials Legislation DEA Patients 230

Cannabis Law Report

AUGUST 12, 2021

Drug Enforcement Administration’s (DEA) refusal to accommodate state and federal right to try laws. US DEA , No. RTT laws permit certain patients who have been diagnosed with life-threatening diseases or conditions access to investigational medications not yet approved for general use by the U.S. 21-70544 (9th Cir.),

DEA 105

DEA Medicine Food Patients 105

Americans for Safe Access

JUNE 6, 2019

In July 2017, four medical cannabis patients joined other advocates in filing a lawsuit against the federal government in the U.S. Drug Enforcement Administration (DEA) to reschedule cannabis, before filing suit. District Court for the Second District of New York. The plaintiffs in the case (originally Washington v.

DEA 228

DEA Patients Cannabis 228

NewsMunchies

MAY 20, 2021

This action by the DEA means researchers will be able to study marijuana from more than one grower. To the extent these MOAs are finalized, DEA anticipates issuing DEA registrations to these manufacturers. million for Ole Miss to grow so it can be doled out in grams to scientists. Rate this blog post.

DEA 98

DEA Chronic Pain Terpenes Packaging 98

Veriheal

JANUARY 24, 2023

But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. After receiving a petition three years prior, the DEA finally answered with action, making plans to deschedule [18F]FP-CIT , a controlled substance derived from cocaine.

DEA 98

DEA Treatment Medicine Pets 98

Cannabis Law Report

MAY 25, 2021

Marijuana Moment reports A bipartisan group of attorneys general from eight U.S. states and the District of Columbia has sided… Read More.

DEA 97

DEA Patients Marijuana 97

Cannabis Cheri

DECEMBER 17, 2021

Locate a nurse and ask how many patients are in the respiratory wing due to their use of tobacco. You will learn that most of the patients in that wing are there for that reason. Now ask how many patients are there because they only smoked marijuana. This article is all about the effects of marijuana on the lungs.

Marijuana 246

Marijuana Media Patients DEA 246

Americans for Safe Access

SEPTEMBER 25, 2024

What's Inside For September 2024: DEA Hearing Delay on Cannabis Rescheduling Patients caught in the middle of CA Hemp Product Ban ASA releases What’s in Your Cannabis? A Patient & Consumer Guide to Navigating Cannabis Safety. Learn More about ASA Member Benefits & Join Today!

DEA 147

DEA Programs Patients Safety 147

Veriheal

JUNE 29, 2021

While they offer approved clinical trials that can offer patients the ability to try potential therapeutic options, many patients are unable to participate in clinical trials, and this is where the importance of the Right to Try programs comes into play. A Push by Patients. Patients Are Not In This Alone.

Therapy 65

Therapy DEA Patients Clinical Trials 65

FloridaMarijuana.net

JULY 8, 2018

PTSD patients lack the necessary endocannabinoids to fill the receptor sites properly. Medical marijuana and cannabinoids can be used to treat a patient’s physical and psychological health, alleviating the debilitating symptoms of PTSD. The study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs).

Strains 190

Strains Indica Hybrid Research and Development 190

Americans for Safe Access

JULY 22, 2024

Healthcare Experts & Cannabis Stakeholders Clear the Smoke on Cannabis Scheduling: Join a Physician, Pharmacist, Researcher, Caregiver, Veteran, Patients, and Patient Advocates as They Bring the Rescheduling Debate to Life Washington, DC – Public comment closes today on the Department of Justice’s (DOJ) proposed rule to move cannabis (marijuana) (..)

Media 130

Media DEA Patients Marijuana 130

Cannabis Law Report

SEPTEMBER 12, 2021

I certainly hope that other states follow Nevada’s lead and provide reassurances to licensed veterinarians that they can administer CBD or talk about it with patients without fear of facing disciplinary proceedings,” he said. But do medical cannabinoids actually help animal patients? Although products containing 0.3% A simple question.

Patients 105

Patients Pets Seed-To-Sale Cannabinoids 105

United Patients Group

JANUARY 15, 2023

However, the DEA and FDA still consider CBD a drug regulated under the Schedule I classification. The DEA definition of a Schedule 1 substance is : Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Book a consultation today.

THC 130

THC CBD DEA Cannabinoids 130

Cannabis Law Report

DECEMBER 7, 2021

On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.

DEA 52

DEA Patients Therapy Access 52

Veriheal

JUNE 22, 2021

While the federal government still holds medical cannabis or even recreational cannabis from the people clinging to years of draconian prohibition, they are allowing certain individuals to work with the DEA and FDA to study antimicrobial properties of cannabinoid therapies being applied to fighting bacteria such as MRSA.

DEA 66

DEA Access Therapy Cannabinoids 66

Cannabis Law Report

JUNE 3, 2019

Plaintiffs in the case, including medical marijuana patients, told the 2nd U.S. Circuit Court of Appeals that the DEA’s refusal to reschedule cannabis damaged their health and that the federal agency should remove cannabis from Schedule 1. Federal appeals court to DEA: Reconsider marijuana’s Schedule 1 status.

DEA 59

DEA Patients Marijuana Cannabis 59

Cannabis Law Report

FEBRUARY 24, 2023

DEA extends many telemedicine flexibilities adopted during the COVID-19 PHE with appropriate safeguards WASHINGTON – Today, the Drug Enforcement Administration announced proposed permanent rules for the prescribing of controlled medications via telemedicine, expanding patient access to critical therapies beyond the scheduled end of the COVID-19 (..)

DEA 52

DEA Therapy Access Patients 52

Cannabis Law Report

SEPTEMBER 4, 2021

Circuit Court of Appeals to order the federal Drug Enforcement Authority to offer a way for terminally ill patients to try psilocybin, the active chemical in hallucinogenic mushrooms, to treat their anxiety and depression. Forty-one states have passed such laws.

Clinical Trials 109

Clinical Trials Law DEA Patients 109

Medical Marijuana Program Connection

MAY 2, 2024

The US Drug Enforcement Agency (DEA) is moving forward with plans to move marijuana from a Schedule I to a Schedule III controlled substance under the Controlled Substance Act (CSA), the US Department of Justice officials announced this week. First reported by the Associated Press and since confirmed by Medscape. Read More

DEA 53

DEA Marijuana Safety Patients 53

WeedAdvisor

JUNE 1, 2019

The court, citing concerns over marijuana’s Schedule I status and its impact on medical users who need it most, essentially issued an ultimatum to the DEA. Like a child who does not want to clean his or her room, the DEA simply refuses to take any major action, despite the whirlwind of reforms surrounding them on a daily basis.

DEA 55

DEA Marijuana History Cannabis 55

NORML

APRIL 30, 2024

“It is significant for these federal agencies, and the DEA and FDA in particular, to acknowledge publicly for the first time what many patients and advocates have known for decades: that cannabis is a safe and effective therapeutic agent for tens of millions of Americans.”

DEA 356

DEA Patients Cannabis Policy 356

MedicalJane

JUNE 29, 2018

Although this is exciting for many advocates of the plant, many patients that are suffering from ailing health conditions are left wondering what this means for them, and how exactly all of these changes will impact their healthcare options. Do you qualify for medical cannabis? Do you qualify for medical cannabis? Check it out here.

Patients 83

Patients Legalization Conditions Treatment 83

Cannabis Law Report

FEBRUARY 5, 2022

Drug Enforcement Administration (DEA) this week challenging the government’s Schedule I classification of psilocybin, the main psychoactive component of psychedelic mushrooms. Seattle Doctor Files DEA Petition To Reschedule Psilocybin For Medical Use. Marijuana Moment. As part of the suit, attorneys general from eight U.S.

DEA 52

DEA Patients Marijuana 52

Americans for Safe Access

APRIL 2, 2019

The Americans for Safe Access 2019 Unity Conference, themed The Price of Being a Medical Cannabis Patient, featured over a hundred patients from all over America visiting their representatives in Congress and the Senate to promote the Medical Cannabis Control Act of 2019.

Access 101

Access DEA Policy Patients 101

SpeedWeed

MAY 18, 2021

Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis. DEA finally relents.

DEA 52

DEA Research and Development Data Cannabis 52

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Marijuana Lawyer Blog

JANUARY 12, 2019

As our Los Angeles marijuana patient attorneys can explain, the crux of the argument by plaintiffs of the claim, first filed in 2017, is that the designation ignores the merits of the drug for medicinal purposes. Defendants are acting-Attorney General Matthew Whitaker, the acting director of the DEA and the federal government.

DEA 40

DEA Patients Epilepsy Medicine 40

Cannabis Law Report

OCTOBER 4, 2021

One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Cheri

DECEMBER 17, 2021

Locate a nurse and ask how many patients are in the respiratory wing due to their use of tobacco. You will learn that most of the patients in that wing are there for that reason. Now ask how many patients are there because they only smoked marijuana. This article is all about the effects of smoking marijuana and lung health.

Marijuana 130

Marijuana Media Patients DEA 130

Cannabis Law Report

NOVEMBER 20, 2021

he Alabama State Board of Medical Examiners Thursday announced draft rules to govern how physicians can recommend medical cannabis to eligible patients. The draft rules would require physicians to obtain an annual certification permit from the Alabama Board of Medical Examiners if they want to recommend a patient to use medical cannabis.

Patients 52

Patients DEA Dispensary Conditions 52

Canna Law Blog

MARCH 4, 2020

According to the FDA , “once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.” Failure to follow these very specific legal directives can lead to immediate criminal liability under federal law.

Therapy 101

Therapy Legalization Chronic Pain DEA 101